Targeting of Immune Response After Pneumococcal Vaccination

Helsinki University Central Hospital42 enrolled

Overview

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study compares the homing profiles of Pnc-specific plasmablasts in 15 patients with pneumonia and in 15 volunteers receiving Pnc polysaccharide vaccine (PPV) and 12 volunteers receiving Pnc conjugate vaccine (PCV)

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Pneumococcal Pneumonia

Interventions

Pneumococcal polysaccharide vaccineBIOLOGICAL

Pneumococcal polysaccharide vaccine 0.5 ml i.m.

pneumococcal conjugate vaccineBIOLOGICAL

pneumococcal conjugate vaccine 0.5 ml i.m.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Males and females ≥ 18 and \<65 years of age. * General good health. * Written informed consent. * No previous vaccination against Pnc * No previous history of Pnc pneumonia * In pneumonia: Diagnosis of Pnc pneumonia within a week Exclusion Criteria: * \< 18 years, ≥65 of age. * In vaccinees: Acute disease at the time of enrollment. * Pregnancy or lactation. * Known immunodeficiency or immune suppressive treatment. * Any chronic illness that might interfere with the immune response * Alcohol or drug abuse * Any clinically significant history of known or suspected anaphylaxis or hypersensitivity (based on the investigator's judgement).

Locations (4)

University of Helsinki, Haartman institute, Dept. of Bacteriology and Immunology

Helsinki, Finland

Division of Infectious Diseases, HUCH

Helsinki, Finland

Division of Microbiology, HUSLAB, Helsinki University Central Hospital

Helsinki, Finland

University of Turku

Turku, Finland

Outcomes

Primary Outcomes

Expression of homing receptors on circulating plasmablasts in Pnc pneumonia and after vaccination

HR on circulating Pnc-specific plasmablasts are determined in patients with pneumonia on day 7-10, in vaccinees on days 0 and 7

Time frame: Day 0 and Day 7-10

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.